Intermedin (adrenomedullin-2) enhances cardiac contractile function via a protein kinase C-and protein kinase A-dependent pathway in murine ventricular myocytes To evaluate the role of IMD on cardiomyocyte contractile function, electrically paced murine ventricular myocytes were acutely exposed to IMD, and the following indexes were determined: peak shortening (PS), time to PS, time-to-90% relengthening, and maximal velocity of shortening and relengthening. Intracellular Ca 2ϩ was assessed using fura 2-AM fluorescent microscopy. Our results revealed that IMD (10 pM to 10 nM) significantly increased PS and maximal velocity of shortening and relengthening in ventricular myocytes, the maximal effect of which (ϳ46%) was somewhat comparable to those elicited by CGRP (1 nM) and adrenomedullin (100 nM). Exposure of IMD significantly shortened time-to-90% relengthening without affecting time to PS, similar to CGRP and adrenomedullin. IMD also enhanced intracellular Ca 2ϩ release, with a maximal increase of ϳ50%, and facilitated the intracellular Ca 2ϩ decay rate. The IMD-induced effects were abolished by the protein kinase C inhibitor chelerythrine (1 M), downregulation of protein kinase C using phorbol 12-myristate 13-acetate (1 M), and the protein kinase A inhibitor H89 (1 M). Our data suggest that IMD acutely augments cardiomyocyte contractile function through, at least in part, a protein kinase C-and protein kinase A-dependent mechanism. cardiac myocyte; shortening; relengthening ADRENOMEDULLIN (AM) and calcitonin gene-related peptide (CGRP) are homologous peptides with important roles in fluid balance, electrolyte homeostasis, and cardiovascular, neuronal, and endocrine function (2, 5, 20) . Due to their sequence analogy, the calcitonin receptor-like receptor (CRLR) may serve either as a CGRP receptor or as an AM receptor, depending on the coexpression of one of three receptor activity-modifying proteins (RAMP1-3). It is believed that the CRLR/RAMP1 complex functions as a specific CGRP receptor, whereas AM preferentially binds to CRLR/RAMP2 or CRLR/RAMP3 (8, 10) . Both CGRP and AM play key roles in the regulation of cardiac function, including a positive inotropic response on the heart (1, 7, 9, 16) . Recently, a novel member of the calcitonin/CGRP/AM family of peptides, namely intermedin (IMD; or AM-2), was identified (14, 17) . The human IMD gene is believed to encode a prepropeptide of 148 amino acids, which may generate a 47-amino acid mature peptide (IMD ) and a shorter 40-amino acid one (IMD 8 -47 ) by proteolytic cleavage at the NH 2 -terminal proximate basic residues. Intravenous infusion of IMD, like AM and CGRP, has been reported to reduce blood pressure and increase heart rate, suggesting that the peptide may be an important regulator for cardiac function (14, 17, 18) . Unlike CGRP and AM, which exhibit a preferential stimulation of CRLR when coexpressed with RAMP1 and RAMP2 or RAMP3, respectively, IMD represents a nonselective agonist for the RAMP coreceptors (14) . IMD and the CRLR/RAMP complexes are expressed in myocardium (14, 17, 18, 26) , indicating the peptide may act in an autocrine or paracrine manner to regulate heart function. Nonetheless, the role of IMD on cardiac contractile function has only recently been explored (12, 24, 25) . The aim of this study was to determine the direct effects of IMD on cardiomyocyte contractile function and potential signaling mechanisms involved by using isolated murine ventricular myocytes.
MATERIALS AND METHODS

Isolation of murine ventricular myocytes.
The experimental procedure used in this study was approved by the University of Wyoming Animal Use and Care Committee (Laramie, WY). Briefly, adult male FVB mice (body weight ϳ22 g, a total of 7 mice were used for this study) were anesthetized with ketamine/xylazine (5:3, 1.32 mg/kg ip). Hearts were rapidly removed and perfused (at 37°C) with KrebsHenseleit bicarbonate buffer (in mM: 118 NaCl, 4.7 KCl, 1.2 MgSO 4, 1.2 KH2PO4, 25 NaHCO3, 10 HEPES, 11.1 glucose, pH 7.4). The heart was then perfused for 20 min with Krebs-Henseleit bicarbonate containing Liberase Blendzyme 4 (Hoffmann-La Roche, Indianapolis, IN). After perfusion, the left ventricle was removed and minced. The cells were filtered through a nylon mesh (300 m). Extracellular Ca 2ϩ was added incrementally back to 1.25 mM. Isolated myocytes were maintained in a serum-free medium before experimentation (3) .
Cell shortening/relengthening. Mechanical properties of ventricular myocytes were assessed using an IonOptix MyoCam soft-edge system (IonOptix, Milton, MA) (3). In brief, cells were superfused with a buffer containing (in mM) 131 NaCl, 4 KCl, 1 CaCl 2, 1 MgCl2, 10 glucose, 10 HEPES, at pH 7.4. The cells were field stimulated at 0.5 Hz. The myocyte was displayed on a computer monitor using an IonOptix MyoCam camera, which rapidly scans the image area every 8.3 ms such that the amplitude and velocity of shortening/relengthening were recorded with good fidelity. Cell shortening and relengthening were assessed using the following indexes: peak shortening (PS) amplitude, time to 90% PS (TPS), time to 90% relengthening (TR 90), and maximal velocities of shortening (ϩdL/dt) and relengthening (ϪdL/dt).
Intracellular fluorescence measurement. Myocytes were loaded with fura 2-AM (0.5 M) for 10 min, and fluorescence measurements were recorded with a dual-excitation fluorescence photomultiplier system (Ionoptix) (3). Myocytes were imaged through an Olympus (model IX-70) fluor ϫ40 oil objective. Cells were exposed to light emitted by a 75-W lamp and passed through either a 360-or a 380-nm filter (bandwidths were Ϯ15 nm), while being stimulated to contract at 0.5 Hz. Fluorescence emissions were detected between 480 and 520 nm after first illuminating cells at 360 nm for 0.5 s then at 380 nm for the duration of the transient period (1,000-Hz sampling rate). The 360-nm excitation scan was repeated at the end of the protocol, and qualitative changes in intracellular Ca 2ϩ concentration were inferred from the ratio of the fura 2 fluorescence intensity (FFI) at two wavelengths.
Experimental protocols. Myocytes (either fura 2-AM loaded or nonloaded) were equilibrated for a minimum of 1 h before IMD introduction. IMD (IMD 1-47, rat, Phoenix Pharmaceuticals, Belmont, CA) was added to the contractile buffer at the concentration tested for 20 min before myocyte contractile function was determined in electrically paced (0.5 Hz) cells. For comparison purpose, cohorts of cardiomyocytes were also exposed to CGRP (1 nM) or AM (100 nM) for 20 min to evaluate the effect of these peptides on myocyte contractile function. To elucidate whether protein kinase C (PKC) or protein kinase A (PKA) plays a role in IMD-induced cardiac contractile response, cells in some experiments were pretreated with the PKC inhibitor chelerythrine chloride (1 M) or the PKA inhibitor H89 (1 M) for 20 min before IMD (10 nM) was applied for another 20 min. Inhibition of PKC was also achieved via PKC downregulation by incubating cells with phorbol 12-myristate 13-acetate (PMA; 1 M) for 60 min (13) before IMD (10 nM) application for 20 min.
Statistical analyses. For each experimental series, data were presented as means Ϯ SE. Statistical significance (P Ͻ 0.05) for each variable was determined by repeated-measures ANOVA for concentration-dependent response or effect of kinase inhibitors on the IMD response. A Tukey's post hoc test was used where appropriate.
RESULTS
Effect of IMD on myocyte PS.
The average resting cell length of cardiomyocytes used in this study was 115.6 Ϯ 0.8 m (n ϭ 594 cells). IMD exposure did not affect cell shape and percentage of variable cells (ϳ70%) over the concentration range tested (data not shown). Representative traces depicting the effect of IMD (10 nM) and its analogs CGRP (1 nM) and AM (100 nM) on myocyte shortening following 20 min of exposure are shown in Fig. 1A . All three peptides enhanced myocyte shortening amplitude in a comparable manner. None of these peptides affected the resting cell length (Fig. 1B) . IMD, CGRP, and AM significantly enhanced PS amplitude, ϩdL/dt, and ϪdL/dt, with maximal increases between 25.4 and 46.4% (Fig.  1, C and D) . The threshold of IMD-induced augmentation in PS and ϮdL/dt was between 50 and 100 pM followed by a plateau (ϳ46% increase) between 100 pM and 10 nM (Fig. 1,  C and D) . IMD significantly decreased TR 90 without affecting TPS, similar to those elicited by CGRP and AM (Fig. 1, E and  F) . Consistent with its response on PS and ϮdL/dt, the threshold of IMD-induced shortening of TR 90 was between 50 and 100 pM (Fig. 1D) . Interestingly, representative traces in Fig. 2A depict that IMD (10 nM)-induced positive effect on cell shortening was nullified by the PKC inhibitor chelerythrine (1 M) or the PKA inhibitor H89 (1 M). Although resting cell length was not affected by IMD, the kinase inhibitors or PKC activator PMA (which downregulates PKC) (Fig. 2B) , the IMD-elicited effects on PS, ϮdL/dt, and TR 90 were abolished by chelerythrine and H89, indicating involvement of both kinase pathways in IMD-exerted response. Neither chelerythrine nor H89 itself elicited any significant effect on cardiac contractile response (Fig. 2) . To confirm the involvement of PKC pathway, myocytes were incubated with PMA (1 M) for 60 min to downregulate PKC kinase (13) . Although PMA treatment itself significantly attenuated PS and ϮdL/dt as well as shortened TPS (but not TR 90 ) duration, IMD failed to elicit any positive contractile response following PMA treatment (compared with the PMA group) (Fig. 2, C-F) . In addition, the IMD-induced shortening of TR 90 was ablated by PMA treatment (Fig. 2F ). These data confirmed that PKC is likely involved in IMD-induced cardiac contractile response.
Effect of IMD on intracellular Ca 2ϩ properties. The Ca 2ϩ fluorescence indicator fura 2-AM was utilized to evaluate the effect of IMD on intracellular Ca 2ϩ handling. Resting and peak intracellular Ca 2ϩ levels were assessed in electrically stimulated cells (at 0.5 Hz). Representative traces shown in Fig. 3A illustrate a positive effect of IMD (10 nM) on intracellular Ca 2ϩ transients. Increasing concentrations of IMD (0 -10 nM) did not affect the resting levels of intracellular Ca 2ϩ , determined by baseline FFI (Fig. 3B) . Similar to its effect on PS, change in FFI (⌬FFI) in response to the electrical stimuli was enhanced by IMD (Fig. 3C) . However, the threshold of IMDelicited positive response on ⌬FFI was between 1 and 10 nM, reflecting a rightward shift from its threshold on cell shortening response. Intracellular Ca 2ϩ clearance velocity (evaluated by intracellular Ca 2ϩ transient decay rate) was facilitated by IMD, with a threshold between 50 and 100 pM (Fig. 3D) . Similar to the mechanical properties, IMD-induced effects on ⌬FFI and intracellular Ca 2ϩ transient decay rate were abolished by the PKC inhibitor chelerythrine. Chelerythrine itself did not elicit any significant effect on intracellular Ca 2ϩ transients.
DISCUSSION
Initial work from our laboratory (18) and other groups (17) has demonstrated the presence of IMD mRNA and peptide immunoreactivity in the heart. Our present study demonstrates that IMD augments cardiac contractile function and electrically stimulated intracellular Ca 2ϩ transients in isolated murine ventricular myocytes. This raises the possibility that IMD produced in the heart acts in vivo via an autocrine or paracrine mechanism to augment cardiac function, in particular cardiac contractility. This notion is further supported by the evidence that the IMD receptor, the CRLR/RAMP complexes, are expressed in the myocardium (22) . Indeed, Yang and colleagues (24) have demonstrated that IMD protects isolated rat hearts from ischemia/reperfusion injury. In their Langendorff preparations, reperfusion with IMD significantly attenuated the detrimental effects of global ischemia on left ventricular function (24) . Cardiac effects of IMD were also reported by Pan and colleagues in intact animals following intravenous administration and in isolated heart preparations (12). However, their study suggested an inhibitory effect of IMD in contrary to the positive effect seen in this study and elsewhere (24, 25) . Pan and colleagues proposed that the myocardial action of IMD was mediated via G protein coupling to adenylate cyclase, since levels of cAMP in the tissues and perfusion buffers were increased in the presence of the peptide. This is somewhat surprising since activation of adenylate cyclase would be expected to be trigger positive, not negative, chronotropic/ inotropic effects. Earlier study from our laboratory demonstrated that the ␤-adrenergic agonist isoproterenol (1 M) elicits an ϳ50% increase in PS amplitude in the same murine cardiomyocytes (11) , similar to that elicited by IMD. In our hands, the IMD-induced enhancement of contractile function was ablated by inhibition of either PKA or PKC, suggesting that a PKA-/PKC-dependent mechanism is likely involved in IMD-elicited cardiac contractile response. Our study revealed that IMD elicits positive contractile response in isolated murine cardiomyocytes in a manner similar to that elicited by CGRP and AM. In fact, IMD has been reported to activate CGRP and AM receptors (CRLR in association with RAMP1, or RAMPs 2 or 3, respectively) (14, 17), and both CGRP and AM have been demonstrated to exert positive inotropic effects in heart (1, 9, 16), potentially via the CRLR/RAMP complexes (10) . However, the vasodilatory effect of intravenous IMD can only be partially attenuated by CGRP or AM antagonists (14, 18), which seems to be in line with our recent observation that IMD may bind and activate a unique receptor (19) . Furthermore, although IMD may be associated with cAMP accumulation in the hearts (12) , IMD may actually decrease cAMP accumulation in the absence or presence of phosphodiesterase inhibition in at least one tissue other than the heart (19). Thus tissue specificity and second messenger heterogeneity may exist depending on cell type studied, particularly when isolated cell types are examined as opposed to whole organs or the intact organism. Therefore, it is possible that IMD acts through non-CRLR/RAMP receptor complexes to produce its procontractile effects in the myocardium and that, unlike the AM and CGRP, the action of IMD is mediated via Ca 2ϩ mobilization by the inositol trisphosphate generated once PLC is activated. This speculation of PLC involvement in IMD-induced cardiomyocyte contractile response is supported by our observation that chelerythrine and PKC downregulation using PMA nullified IMD-elicited contractile response (intracellular Ca 2ϩ transients for chelerythrine as well). PKC activation is known to stimulate cardiomyocyte contractile function via improved intracellular Ca 2ϩ handling and increased myofilament protein phosphorylation (6) . Nevertheless, our data showed that prolonged PKC activation by PMA itself depressed cardiac contractile function (reduced PS, ϮdL/dt, and shortened TPS). It has been speculated that inhibition of PKC activity in the hearts may improve systolic and diastolic function, whereas chronic activation of PKC may cause a lethal restrictive cardiomyopathy with marked interstitial fibrosis (4). Although direct evidence for IMD-induced activation of PKC in hearts is still lacking, it may be speculated that excessively high levels of IMD may cause chronic PKC activation and promote the development of heart failure. Clearly, this hypothesis on PKC activation in response to IMD merits further research in the setting of both physiology and pathophysiology.
In this study, acute IMD exposure to murine ventricular myocytes directly enhanced PS by ϳ45%. The IMD-induced maximal increase in myocyte shortening amplitude was associated with an augmentation of ϮdL/dt as well as intracellular Ca 2ϩ release (⌬FFI) in response to electrical stimuli. Although the mechanism(s) for IMD-induced augmentation of cardiomyocyte contractile function is not clear, the effect of IMD on PKC, PKA, as well as intracellular Ca 2ϩ release may all play -storage organelles, such as the sarcoplasmic reticulum and mitochondria. These findings are consistent with the ability of AM and CGRP to rapidly facilitate intracellular Ca 2ϩ release and enhance cardiac contractility via mechanisms involving Ca 2ϩ release from intracellular ryanodine-and thapsigargin-sensitive Ca 2ϩ stores, activation of PKA and PKC, as well as Ca 2ϩ influx through L-type Ca 2ϩ channels (7, 16 ). In conclusion, our study reveals that IMD stimulates cardiomyocyte contractile function mediated, at least in part, by increased intracellular Ca 2ϩ transients and activation of PKC as well as PKA. Further investigation is warranted to examine the effect of IMD on sarcoplasmic reticulum Ca 2ϩ release, membrane Ca 2ϩ channels, and Ca 2ϩ regulatory proteins, which should be essential to the understanding of the role of IMD on cardiac contractile function. The physiological relevance of the IMD-elicited cardiac stimulatory effect is unknown at this time. However, our data match findings in isolated heart preparations (25) , suggesting that, like CGRP and AM, IMD may be a physiologically important, cardioprotective peptide. The procontractile actions of IMD may also complement additional actions previously demonstrated in brain to augment sympathetic activity (18) , stimulate stress hormone secretion (21) , and, in so doing, play an integrative role in the response to immediate danger or perceived stress.
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